Independent
Tenure on this board
13.6 yrs
Also a director at
Allogene Therapeutics Inc (ALLO)
Meeting calendar
URGN · Annual meeting · Tuesday, August 26, 2025
Urogen Pharma Ltd
7 nominees · 6 ballot items.
Six proposals are up for vote at the 2025 annual meeting: (1) Election of seven board nominees; (2) Amendments to the 2024 non-employee director and officer compensation policy; (3) Amendments to the 2017 Equity Incentive Plan increasing authorized shares by 2,750,000; (4) Advisory vote on executive compensation; (5) Advisory vote on the frequency of advisory votes on executive compensation; (6) Ratification of engagement of PwC as auditor through 2026.
Market cap
$1.8B
1Y TSR
+211.4%
Board grade
C
Record date
Jul 14, 2025
Filing
DEF 14A
Meeting concluded · Aug 26, 2025
Follow how the vote landed and what changed on Urogen Pharma Ltd’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot6
- 1
Election of Directors
ManagementBoard: FORElection to the Board of seven nominees presented by the Board to hold office until our next annual meeting of shareholders.
- 2
Amendments to the Company’s 2024 Non-Employee Director and Officer Compensation Policy
ManagementBoard: FORApprove the Amended and Restated Non-Employee Director and Officer Compensation Policy (A&R Policy) updating share-based compensation limits and other terms.
- 3
Amendments to the Company’s 2017 Equity Incentive Plan
ManagementBoard: FORApprove the Amended 2017 Equity Incentive Plan increasing the number of shares available for issuance by 2,750,000 and related features.
- 4
Advisory Vote on Executive Compensation
ManagementBoard: FORNon-binding advisory vote on the compensation of the Company’s named executive officers, as disclosed in the proxy statement.
- 5
Advisory Vote on the Frequency of Shareholder Advisory Votes on Executive Compensation
ManagementBoard: FORAdvisory vote to indicate the preferred frequency (1 Year, 2 Years, or 3 Years) for future say-on-pay votes.
- 6
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the 2026 annual meeting.
Director elections
Nominees on the ballot7
Not independent
Tenure on this board
7.5 yrs
Also a director at
Allogene Therapeutics Inc (ALLO)
Independent
Tenure on this board
8.8 yrs
Also a director at
Olema Pharmaceuticals Inc (OLMA)Autolus Therapeutics PLC (AUTL)
Independent
Tenure on this board
10.6 yrs
Independent
Tenure on this board
2.9 yrs
Also a director at
Eledon Pharmaceuticals Inc (ELDN)
Independent
Tenure on this board
3.8 yrs
Also a director at
Glaukos Corp (GKOS)
Independent
Tenure on this board
3.6 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 9.3% | 4,543,895 | $82M |
| 2 | TORONTO DOMINION BANK | 5.4% | 2,616,714 | $47M |
| 3 | MORGAN STANLEY | 5.1% | 2,501,554 | $45M |
| 4 | Kynam Capital Management, LP | 4.6% | 2,247,393 | $40M |
| 5 | Jefferies Financial Group Inc. | 4.5% | 2,199,652 | $40M |
| 6 | BlackRock, Inc. | 3.6% | 1,736,185 | $31M |
| 7 | Paradigm Biocapital Advisors LP | 3.5% | 1,703,949 | $31M |
| 8 | ACORN CAPITAL ADVISORS, LLC | 3.4% | 1,673,420 | $30M |
| 9 | SG Americas Securities, LLC | 3.4% | 1,657,846 | $30M |
| 10 | AMERICAN CENTURY COMPANIES INC | 3.4% | 1,637,570 | $29M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Urogen Pharma Ltd’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.9B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$2.0B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.2B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Reference
Frequently asked questions
- When is the Urogen Pharma Ltd 2025 annual meeting?
- Urogen Pharma Ltd (URGN) holds its 2025 annual shareholder meeting on Tuesday, August 26, 2025.
- What is the record date for the Urogen Pharma Ltd 2025 meeting?
- The record date for the Urogen Pharma Ltd 2025 meeting is Monday, July 14, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Urogen Pharma Ltd's 2025 meeting?
- The board is presenting 7 director nominees at the Urogen Pharma Ltd 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Urogen Pharma Ltd 2025 meeting?
- Shareholders will vote on 6 proposals at the Urogen Pharma Ltd 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.